Comparative Pharmacology
Head-to-head clinical analysis: SEZABY versus ZYPREXA ZYDIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEZABY versus ZYPREXA ZYDIS.
SEZABY vs ZYPREXA ZYDIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C receptors, dopamine D1-D4 receptors, muscarinic M1-M5 receptors, histamine H1 receptors, and alpha1-adrenergic receptors. Antagonism at D2 and 5-HT2A receptors is primarily responsible for its antipsychotic effects.
58 mg subcutaneously once monthly (every 30 days).
10 mg orally once daily; range 5-20 mg once daily. Initial dose 5-10 mg, titrate by 5 mg weekly. Maximum 20 mg/day. Orally disintegrating tablet.
None Documented
None Documented
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life: ~30 hours (range 21–54 hours) in healthy adults; prolonged in elderly (mean 51.8 h) and hepatic impairment.
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Renal: ~57% (as metabolites); Fecal: ~30% (as metabolites); Unchanged olanzapine in urine <7%.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic